Drug Profile
Research programme: monoclonal antibodies - Humabs BioMed
Alternative Names: RVC 20; RVC 58Latest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Humabs BioMed
- Developer Humabs BioMed; Swiss Tropical and Public Health Institute; University of California at Berkeley
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Infections
Highest Development Phases
- No development reported Campylobacter infections; Cancer; Dengue; Ebola virus infections; Escherichia coli infections; Hepatitis B; Herpes simplex virus infections; Influenza B virus infections; Metapneumovirus infections; Middle East respiratory syndrome coronavirus; Norovirus infections; Rabies; Respiratory syncytial virus infections; Severe acute respiratory syndrome; Staphylococcal infections; Zika virus infection
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for research development in Campylobacter-infections in Switzerland (Parenteral)
- 28 Jun 2021 No recent reports of development identified for research development in Escherichia-coli-infections in Switzerland (Parenteral)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Zika-virus-infection in Switzerland (Parenteral)